

MEC Dynamics Corp - Press Release

MEC Dynamics Corp signs distribution agreement for its *Avie™ A1c* Point-of-Care system

MEC signs Quest Diagnostics HemoCue AB subsidiary as exclusive distributor in the U.S. and Europe

Santa Clara, CA, June 2nd, 2009 – MEC Dynamics Corp (MEC) today announced it has signed an agreement with **HemoCue AB**, an international company in the field of point-of-care (PoC) testing and a subsidiary of **Quest Diagnostics Incorporated** (NYSE: DGX), for the exclusive distribution of its *Avie™ A1c* hemoglobin A1c (HbA1c) system in the United States and Europe.

“MEC is pleased to be working with Quest Diagnostics subsidiary HemoCue AB, an international provider of diagnostic testing,” said Manny Mpock, Chief Executive Officer, MEC Dynamics Corp. “We designed the *Avie™ A1c* to give physicians affordable access to a point-of-care HbA1c test that delivers ease of use and results they can rely on. That the *Avie™ A1c* has been selected to enhance the HemoCue portfolio of diabetes point-of-care tests speaks to a shared commitment between our two companies – to put quality test results at the point of care.”

“MEC’s *Avie™ A1c* test will be an important addition to the HemoCue suite of point-of-care tests for efficient diabetes management,” said Niels Christiansen, HemoCue AB Managing Director. “Physicians can test for and diagnose the disease using the HemoCue Glucose 201 systems, and they can monitor for diabetes-related complications with the HemoCue Albumin 201 test for microalbuminuria. The *Avie™ A1c* will help physicians track a patient’s glycemic control over time, and it will help them to do so within minutes, making it an important tool that can help to facilitate direct patient feedback and informed treatment decisions at the point of care.”

The MEC *Avie™ A1c*, which is used for the quantitative measurement of HbA1c in diabetic patients, has U.S. Food and Drug Administration (FDA) 510(k) clearance and has been granted an FDA CLIA waiver, which allows non-laboratory trained physicians and other health care professionals in any health care facility with a CLIA Certificate of Waiver in the U.S. to use the test. MEC’s *Avie™ A1c* is the first in its range of rapid PoC tests that will use its patented platform to offer high performance and affordable diagnostics for the physician’s office as well as home testing.

Using blood from a finger prick and a single use disposable cartridge, HbA1c results are displayed on the screen of the handheld reader within three minutes. The *Avie™ A1c* is NGSP certified for accuracy and CLIA Waived by the FDA. HemoCue AB's distribution of the *Avie™ A1c* test is expected to begin in Fall 2009.

About MEC's Platform Technology

MEC has developed a patented innovative micro-fluidics point-of-care platform capable of performing a range of enzymatic, general chemistry as well as immunochemistry assays. All of MEC diagnostics systems are designed to be simple, accurate and affordable for the global market.

About MEC Dynamics

MEC is a medical device company developing and manufacturing point-of-care diagnostic products, using its proprietary technology.

MEC's devices are designed for use in the physician's office as well as the patient's home. They enable the 'real time' measurement of key blood analytes for early detection and more effective management of a variety of diseases including diabetes, cardiovascular diseases and cancer.

Chronic and life-threatening diseases occurring in both industrial and developing countries could be better treated through early detection and monitoring. MEC aims to be a global developer and manufacturer of point-of-care diagnostic products using its technology platform.

MEC's news releases and other information are available on the company's web site at www.mecdynamics.com.

Contact

Manny Mpock
Chief Executive Officer

MEC Dynamics Corp
2225 Martin Ave, Suite 1
Santa Clara, CA 95050
USA

Email: mecinfo@MECDynamics.com
Tel: +1 408.844.9280
Fax: +1 408.844.9285

Commercial Contact

Dr. Kim Tan
Chairman

Springhill Management Ltd
PO Box 822
Guildford, Surrey GU5 0ZR
UK

Email: info@springhilluk.com
Tel: +44 1483 890 574
Fax: +44 1483 894 333
